Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Preclinical safety and efficacy of an allogeneic adipose-derived mesenchymal stem cell medicinal product for rotator cuff repair: a two-phase experimental study.

Lopiz Y., Ponz-Lueza V., Arvinius C., Rodríguez-Bobada C., Rojo-Pérez F., Tornero-Esteban P.

Clinical Trial with a reported sample of 24 on Tendon Injury, Rotator Cuff, published in J Shoulder Elbow Surg (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Shoulder Elbow Surg (2026)
Country
United States
Reported sample size
24
Source database
PubMed
PMID
42297179
DOI
10.1016/j.jse.2026.06.005

Abstract (original English)

Background Cell therapy with adipose-derived mesenchymal stem cells (ASCs) is a promising biological augmentation strategy for rotator cuff repair; however, before clinical translation, regulatory frameworks mandate rigorous preclinical characterization of safety. We report the complete preclinical program evaluating both the safety of an allogeneic ASC-based cell therapy medicinal product (CTMP) and its efficacy in a chronic rotator cuff tear model. Methods Phase I (safety, 164 immunodeficient nude BALB/c mice) assessed toxicity, biodistribution, and tumorigenicity after intra-articular and intravenous administration at doses ranging from 10× to 1,000× the projected clinical dose. Toxicity was evaluated by biochemical panels and full-body histopathology at 90 days. Biodistribution was quantified by fluorodeoxyglucose-positron emission tomography/computed tomography (days 45 and 90) and human-specific quantitative polymerase chain reaction (Alu-repeat) at 90 days. Tumorigenicity used an HT-29 positive-control model. Phase II (efficacy, 48 Sprague-Dawley rats) used a validated 4-week chronic supraspinatus tear-and-repair model; after repair, animals received ASCs in suspension (n = 24) or Hypothermosol vehicle (n = 24) and were assessed histologically (Åström-Rausing scale) and biomechanically (Instron 4,411) at 4 months. Results In Phase I, no biochemical or histopathological t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research